Impact of using a non-diabetes-specific risk calculator on eligibility for statin therapy in type 2 diabetes

Diabetologia

Volumn 52, Issue 3, 2009, Pages 394-397

  Price, H C ^a   Coleman, R L ^a   Stevens, R J ^a   Holman, R R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical science; Macrovascular disease; Mathematical modelling and simulation

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE DURATION; ETHNIC GROUP; FEMALE; FRAMINGHAM CVD RISK EQUATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; UKPDS RISK ENGINE; UNITED KINGDOM;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PATIENT SELECTION; RISK ASSESSMENT;

EID: 59449101722     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-008-1231-5     Document Type: Article

References (17)

1. J Stamler O Vaccaro J Neaton D Wentworth 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial Diabetes Care 16 434 444
2. National Institute for Health and Clinical Excellence (2006) Statins for the prevention of cardiovascular disease. NICE, London. Available from http://www.nice.org.uk/TA094, accessed 7 November 2008
3. R D'Agostino R Vasan M Pencina 2008 General cardiovascular risk profile for use in primary care: The Framingham Heart Study Circulation 117 743 753
4. R Coleman R Stevens R Holman 2007 Estimating cardiovascular disease risk for individuals with type 2 diabetes: the new UKPDS Risk Engine Diabetic Medicine 24 Suppl 1 56 Abstract
5. R Coleman R Stevens R Retnakaran R Holman 2007 Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes Diabetes Care 30 1292 1293
6. K Asimakopoulou T Skinner J Spimpolo S Marsh C Fox 2008 Unrealistic pessimism about risk of coronary heart disease and stroke in patients with type 2 diabetes Patient Educ Couns 71 95 101
7. A Farmer A Wade E Goyder 2007 Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial BMJ 335 132
8. E Gregg G Qiuping Y Cheng K Venkat-Narayan C Cowie 2007 Mortality trends in men and women with diabetes, 1971 to 2000 Ann Intern Med 147 149 155
9. http://www.statistics.gov.uk/cci/nugget.asp?id=273, accessed 26 August 2008
10. M Maggin R Raschetti G Traversa 2004 The cerivastatin withdrawal crisis: a "post-mortem" analysis Health Policy 69 151 157
11. DM Lloyd-Jones MG Larson A Beiser D Levy 1999 Lifetime risk of developing coronary heart disease Lancet 353 89 92
12. UK Prospective Diabetes Study Group 1991 UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance Diabetologia 34 877 890
13. S Grundy R Pasternak P Greenland S Smith V Fuster 1999 AHA/ACC Scientific Statement. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology Circulation 100 1481 1492
14. R Hiller R Sperduto M Podgor F Ferris P Wilson 1988 Diabetic retinopathy and cardiovascular disease in type II diabetics. The Framingham Heart Study and the Framingham Eye Study Am J Epidemiol 128 402 409
15. G De Backer E Ambrosioni K Borch-Johnsen 2003 European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice Eur Heart J 24 1601 1610
16. B McCrindle L Ose A Marais 2003 Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial J Pediatrics 143 74 80
17. N Day S Oakes R Luben 1999 EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer Br J of Cancer 80 Suppl 1 95 103